Accordingly, VGSC blockade could eliminate this component of immune response and could form the basis of mono- and/or combination immunotherapy with tumor vaccines or with PD-1 blockade to dampen TME immunosuppression, overcome PD-1 resistance and enhance patient responses (149). Here, PDCD1 is linked to neoplasm.